Jupiter Topco LLC purchased a new stake in shares of Omeros Corporation (NASDAQ:OMER – Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 30,500 shares of the biopharmaceutical company’s stock, valued at approximately $290,000.
Other institutional investors have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its position in Omeros by 85.2% in the first quarter. Dimensional Fund Advisors LP now owns 179,594 shares of the biopharmaceutical company’s stock valued at $1,897,000 after buying an additional 82,646 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Omeros during the second quarter worth $57,484,000. Ancora Advisors LLC acquired a new position in shares of Omeros during the second quarter worth $1,605,000. Bank of America Corp DE lifted its stake in shares of Omeros by 57.8% in the 1st quarter. Bank of America Corp DE now owns 204,805 shares of the biopharmaceutical company’s stock valued at $2,163,000 after acquiring an additional 74,997 shares during the last quarter. Finally, Deutsche Bank AG bought a new position in shares of Omeros in the 2nd quarter valued at $714,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on the company. Weiss Ratings upgraded Omeros from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, September 3rd. Zacks Research lowered Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Wall Street Zen upgraded Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Omeros in a research note on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $38.00.
Omeros Stock Up 0.9%
Shares of Omeros stock opened at $19.12 on Wednesday. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of 14.94 and a beta of 2.60. Omeros Corporation has a twelve month low of $3.94 and a twelve month high of $19.65. The company’s fifty day moving average is $13.89 and its 200 day moving average is $12.39.
Omeros (NASDAQ:OMER – Get Free Report) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.29. The company had revenue of $28.53 million for the quarter, compared to the consensus estimate of $12.69 million. As a group, equities analysts anticipate that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Omeros news, Director Thomas J. Cable sold 15,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $18.45, for a total transaction of $276,750.00. Following the completion of the sale, the director owned 35,067 shares of the company’s stock, valued at approximately $646,986.15. This represents a 29.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Peter B. Cancelmo sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $18.54, for a total transaction of $463,500.00. Following the transaction, the vice president owned 200 shares of the company’s stock, valued at approximately $3,708. The trade was a 99.21% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 95,906 shares of company stock valued at $1,780,205 over the last three months. 10.50% of the stock is owned by insiders.
About Omeros
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
Recommended Stories
- Five stocks we like better than Omeros
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
